Drug Profile
Research programme: antibody therapeutics - ImmuNext/Roche
Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator ImmuNext
- Developer ImmuNext; Roche
- Class
- Mechanism of Action VISTA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 20 Dec 2016 Preclinical trials in Autoimmune disorders in USA (Parenteral)